Interní Med. 2017; 19(2): 82-84 | DOI: 10.36290/int.2017.014

Augmentation therapy for emphysema due to alpha-1 antitrypsin deficiency

MUDr. Jan Chlumský, Ph.D.
Pneumologická klinika 1. LF UK, Thomayerova nemocnice, Praha

Alpha-1 antitrypsin (AAT) deficiency is one of the most common hereditary disorder of the adult age. It is mainly associated

with the early developement of COPD and hepatic injury. These patients develop emphysema in younger age and have poorer

prognosis due to accelerated decline of lung functions. The augmentation therapy with human AAT slows down the rate of lung

destruction and improve prognosis of deficient subjects.

Keywords: COPD, emphysema, alpha-1 antitrypsin, augmentation therapy

Published: April 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Chlumský J. Augmentation therapy for emphysema due to alpha-1 antitrypsin deficiency. Interní Med. 2017;19(2):82-84. doi: 10.36290/int.2017.014.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. O'Donnell DE, Elbehairy AF, Faisal A, Webb KA, Neder JA, Mahler DA. Exertional dyspnoea in COPD: the clinical utility of cardiopulmonary exercise testing. Eur Respir Rev. 2016; 25(141): 333-347. doi:10.1183/16000617.0054-2016. Go to original source... Go to PubMed...
    2. Koblizek V, Chlumsky J, Zindr V, et al. Chronic Obstructive Pulmonary Disease: Official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care. Biomed Pap. 2013; 157(2): 189-201. doi:10.5507/bp.2013.039. Go to original source...
    3. Stoller JK. American Thoracic Society/European Respiratory Society Statement. Am J Respir Crit Care Med. 2003; 168(7): 818-900. doi:10.1164/rccm.168.7.818. Go to original source...
    4. Stoller JK, Aboussouan LS. A Review of ?1-Antitrypsin Deficiency. Am J Respir Crit Care Med. 2012; 185(3): 246-259. doi:10.1164/rccm.201108-1428CI. Go to original source...
    5. Kelly E, Greene CM, Carroll TP, McElvaney NG, O'Neill SJ. Alpha-1 antitrypsin deficiency. Respir Med. 2010; 104(6): 763-772. doi:10.1016/j.rmed.2010.01.016. Go to original source... Go to PubMed...
    6. Vreim CE. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med. 1998; 158(1): 49-59. doi:10.1164/ajrccm.158.1.9712017. Go to original source...
    7. Stockley RA, Parr DG, Piitulainen E, Stolk J, Stoel BC, Dirksen A. Therapeutic efficacy of ?-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir Res. 2010; 11(1): 136. doi:10.1186/1465-9921-11-136. Go to original source...
    8. Chapman KR, Burdon JGW, Piitulainen E, et al. Intravenous augmentation treatment and lung density in severe ?1 anti-trypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet. 2015; 386(9991): 360-368. doi:10.1016/S0140-6736(15)60860-1. Go to original source...
    9. Chlumský J. CHOPN s prokázanou deficiencí alfa-1 antitrypsinu. In: Kolek V, ed. Doporučené Postupy v Pneumologii. Prague: Maxdorf; 2016: 46-54.
    10. Stockley RA, Miravitlles M, Vogelmeier C. Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach. Orphanet J Rare Dis. 2013; 8: 1. doi:10.1186/1750-1172-8-149. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.